CymaBay Therapeutics (CBAY) Stock Highlights

32.48 | +0%

2024-11-21 02:08:22

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.

Statistics

Range Today

32.48 32.48

Volume Today 0

Range 1 Year

7.26 32.5

Volume 1 Year 611.72M

Range 3 Year

1.67 32.5

Volume 3 Year 964.38M

Range 10 Year

0.82 32.5

Volume 10 Year 2.43B

Highlights

Market Capitalization 3.73B (mid)

Floating Shares 96.64M

Current Price 32.48

Price To Earnings 0

Price To Revenue 110.92

Price To Book 12.65

Earnings Per Share -0.99

Payout Ratio 0%

Performance

Latest 0%

1 Month +0.78%

3 Months +40%

6 Months +120.8%

1 Year +279.88%

3 Years +636.51%

5 Years +172.25%

10 Years +306%

Benchmarks

Market Capitalization

50 / 368

Gross Profits

189 / 278

Total Revenue

142 / 300

Total Rank

102 / 368

Free Cashflow

212 / 352

Performance 5 years

55 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.